ARMING THE IMMUNE SYSTEM TO FIGHT CANCER（武装的免疫系统对抗癌症）.pdfVIP

ARMING THE IMMUNE SYSTEM TO FIGHT CANCER OncoSec’s ImmunoPulse™ platform is a powerful technology for delivering DNA-based therapeutics directly into tumor cells. Studies to-date have focused on the intratumoral delivery of DNA expressing interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. Positive data from these studies have validated ImmunoPulse™ as a viable delivery platform and laid the groundwork for the Company’s current expansion into new immune targets and tumor indications. ImmunoPulse™ IL-12 demonstrated significant clinical efficacy in a Favorable safety profile supports ongoing clinical development multi-center Phase II trial in patients with metastatic melanoma ImmunoPulse™ IL-12 is safe and well-tolerated across multiple 31% best overall response treatment cycles 14% complete response No treatment-related grade 4 or 5 adverse events reported 48% disease control rate No treatment-related serious adverse events reported 50% of patients with regression in at least one untreated lesion Extensive RD and preclinical operations ImmunoPulse™ IL-12 may enhance response to anti-PD-1 and other Researching the delivery of any DNA-encoded immunomodulatory immune checkpoint therapies molecules to overcome tumor immune tolerance Checkpoint therapies are projected to become standard of care Exploring